美国 · 财经报刊 · Investor's Business Daily
Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

详细摘要
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab. The post Summit Crumbles After FDA…
Summit Therapeutics (SMMT) stock crashed Monday after the Food and Drug Administration rejected its Merck (MRK)-rivaling lung cancer drug, ivonescimab. Leerink Partners analyst Daina Graybosch wasn't surprised, noting the FDA said ivonescimab in combination with chemotherapy would need to improve overall survival to win approval. Overall survival is how long patients live before dying of any cause. The regimen failed…
文章开头,摘自Investor's Business Daily。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.investors.com)